Progyny (PGNY) Stock Overview
A benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
PGNY passed our risk checks.
PGNY Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Progyny, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.33 |
| 52 Week High | US$26.76 |
| 52 Week Low | US$13.39 |
| Beta | 1.34 |
| 1 Month Change | -2.02% |
| 3 Month Change | -3.05% |
| 1 Year Change | 27.88% |
| 3 Year Change | -44.29% |
| 5 Year Change | -22.15% |
| Change since IPO | 33.81% |
Recent News & Updates
At US$22.49, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Aug 02
Progyny (NASDAQ:PGNY) Might Have The Makings Of A Multi-Bagger
Jul 13Recent updates
At US$22.49, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Aug 02Progyny (NASDAQ:PGNY) Might Have The Makings Of A Multi-Bagger
Jul 13Progyny: Robust Expectations In 2025 Amid Growing Expenses (Hold)
May 28Progyny, Inc.'s (NASDAQ:PGNY) CEO Will Probably Struggle To See A Pay Rise This Year
May 16The Price Is Right For Progyny, Inc. (NASDAQ:PGNY)
May 13At US$22.90, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Apr 25Progyny, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 02The Play On Progyny: Don't Chase, But Watch And Wait
Feb 06Capital Allocation Trends At Progyny (NASDAQ:PGNY) Aren't Ideal
Jan 30Progyny: The Growth Story Remains Intact
Jan 15Progyny, Inc.'s (NASDAQ:PGNY) P/E Is Still On The Mark Following 28% Share Price Bounce
Jan 12Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Jan 03The Bottom Fishing Club: Progyny Reverses On Heavy Insider Buying
Dec 31Progyny: Rating Downgrade On Uncertain Growth Outlook
Nov 26Progyny's (NASDAQ:PGNY) Solid Earnings Have Been Accounted For Conservatively
Nov 21Progyny: After A Terrible Year, I'm Out (Rating Downgrade)
Nov 18Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
Oct 21Progyny: Poor Year Raises Concerns For Future (Downgrade)
Oct 15Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
Sep 29
Expanding Market Reach And Enhancing Services Spur Optimistic Revenue And Profit Forecasts
Anticipated decrease in ART cycle utilizations may negatively affect revenue due to lower fertility treatment rates.Progyny: Downgrading As Uncertainties Increase
Aug 15Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing
Aug 11At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 20Progyny: Recent Stock Decline Provides Buying Opportunity
Jul 12Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall
Jun 23Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Jun 10Progyny: No Change To Long-Term Outlook
Jun 04Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24Shareholder Returns
| PGNY | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.7% | -1.3% | -1.5% |
| 1Y | 27.9% | -18.1% | 14.4% |
Return vs Industry: PGNY exceeded the US Healthcare industry which returned -19.5% over the past year.
Return vs Market: PGNY exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| PGNY volatility | |
|---|---|
| PGNY Average Weekly Movement | 5.4% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PGNY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PGNY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 678 | Pete Anevski | www.progyny.com |
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services.
Progyny, Inc. Fundamentals Summary
| PGNY fundamental statistics | |
|---|---|
| Market cap | US$1.75b |
| Earnings (TTM) | US$53.12m |
| Revenue (TTM) | US$1.24b |
Is PGNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PGNY income statement (TTM) | |
|---|---|
| Revenue | US$1.24b |
| Cost of Revenue | US$964.52m |
| Gross Profit | US$277.44m |
| Other Expenses | US$224.32m |
| Earnings | US$53.12m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 22.34% |
| Net Profit Margin | 4.28% |
| Debt/Equity Ratio | 0% |
How did PGNY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 17:20 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Progyny, Inc. is covered by 22 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhilin Long | Berenberg |
| Nisala Weerasuriya | Berenberg |
| Allen Lutz | BofA Global Research |